Using CDK2 inhibitors to prevent hearing loss caused by cancer treatment
Official title: CDK2 inhibitors for protecting hearing loss
Funded at Ting Therapeutics, INC. · NIH-11228819 · Data updated 2026-11-12
This study is testing a new drug called TT001 to see if it can help prevent hearing loss in cancer patients who are receiving cisplatin chemotherapy, so they can keep their hearing while still getting the treatment they need.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ting Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | December 9, 2019 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $174,684 |
| NIH project number | 6R44DC018463-05 |
| Project ID | NIH-11228819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving cisplatin treatment and are at risk of developing hearing loss.
✕Less likely to help
Patients who are not undergoing cisplatin treatment or those who do not have a risk of hearing loss may not benefit from this research.
What this research studies
This research focuses on developing a drug called TT001, which is a CDK2 inhibitor, to protect patients from hearing loss that can occur as a side effect of cisplatin, a common chemotherapy drug. The study involves testing the effectiveness of TT001 in preventing cell death in cochlear cells, which are crucial for hearing, while ensuring that it does not interfere with the cancer-fighting properties of cisplatin. Patients may benefit from this research as it aims to provide a solution for the significant number of cancer patients who experience hearing loss due to their treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that prevents hearing loss in cancer patients undergoing cisplatin therapy.
How similar studies have gone: Previous research has shown promise in using CDK2 inhibitors for protecting against cell death, making this approach a potentially viable option.
Where this research is happening
-
Ting Therapeutics, INC.
San Diego, United States Active
Researchers
- Principal investigator: Huang, Yunlong — Ting Therapeutics, INC.
- Study coordinator: Huang, Yunlong
Related research
Other NIH-funded projects on the same topics.
-
Noise-related hearing loss and its link to Alzheimer's progression
Researchers are looking at whether hearing damage from loud noise speeds memory loss and dementia in people at risk for Alzheimer's.
-
Audiological rehabilitation for children with unilateral hearing loss
A research project aims to help children who hear with one ear by testing ways to improve their hearing and communication through targeted audiology interventions.
-
Choosing the right hearing device for kids with moderate-to-severe hearing loss
This grant explores which hearing device—hearing aids or cochlear implants—works best for children aged 0-11 with moderate-to-severe hearing loss.
-
Noise-related hearing loss and brain-to-ear feedback in hearing protection
A small, patient-friendly study will look at how loud noise changes the brain’s control over hearing and whether this affects conditions like tinnitus or sensitivity to sound.
-
How loud noise can change the brain's sound decisions
This project looks at how loud noise-related hearing loss may affect how people process sounds and make quick decisions about what they hear.
-
Understanding how tactile language and wearable tech can help DeafBlind children learn and use language
A study at Gallaudet University tests a new tactile language and wearable haptic devices to help DeafBlind children build early language and everyday life skills.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.